open access

Vol 16, No 3 (2012)
REVIEV
Published online: 2012-08-02
Get Citation

Telmisartan in hypertensive treatment — practicalities

Krystyna Widecka
Nadciśnienie tętnicze 2012;16(3):169-178.

open access

Vol 16, No 3 (2012)
REVIEV
Published online: 2012-08-02

Abstract

Blockade of the renin-angiotensin system plays a pivotal role
in the treatment of high blood pressure and prevention of
target organ damage. Telmisartan is an angiotensin II receptor
blocker displaying beneficial unique pharmacologic
properties, metabolic effects, antihypertensive efficacy in
monotherapy and combinations and good tolerance. Clinical
studies confirm that telmisartan improves endothelial function,
insulin sensitivity and lipid profiles, reduces arterial stiffness,
left ventricular hypertrophy and the recurrence of atrial
fibrillation. In addition, telmisartan improves renal function
and has potential beneficial effects on prevention of cerebrovascular
disease. The ONTARGET study has shown that
telmisartan provides similar cardiovascular protection

Abstract

Blockade of the renin-angiotensin system plays a pivotal role
in the treatment of high blood pressure and prevention of
target organ damage. Telmisartan is an angiotensin II receptor
blocker displaying beneficial unique pharmacologic
properties, metabolic effects, antihypertensive efficacy in
monotherapy and combinations and good tolerance. Clinical
studies confirm that telmisartan improves endothelial function,
insulin sensitivity and lipid profiles, reduces arterial stiffness,
left ventricular hypertrophy and the recurrence of atrial
fibrillation. In addition, telmisartan improves renal function
and has potential beneficial effects on prevention of cerebrovascular
disease. The ONTARGET study has shown that
telmisartan provides similar cardiovascular protection
Get Citation

Keywords

telmisartan, hypertension, cardiovascular risk, hypertensive treatment

About this article
Title

Telmisartan in hypertensive treatment — practicalities

Journal

Arterial Hypertension

Issue

Vol 16, No 3 (2012)

Pages

169-178

Published online

2012-08-02

Bibliographic record

Nadciśnienie tętnicze 2012;16(3):169-178.

Keywords

telmisartan
hypertension
cardiovascular risk
hypertensive treatment

Authors

Krystyna Widecka

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl